AR020614A1 - Nuevo metodo - Google Patents

Nuevo metodo

Info

Publication number
AR020614A1
AR020614A1 ARP990103577A ARP990103577A AR020614A1 AR 020614 A1 AR020614 A1 AR 020614A1 AR P990103577 A ARP990103577 A AR P990103577A AR P990103577 A ARP990103577 A AR P990103577A AR 020614 A1 AR020614 A1 AR 020614A1
Authority
AR
Argentina
Prior art keywords
human
cells
mammal
administration
new method
Prior art date
Application number
ARP990103577A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Lab Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Lab Pharma filed Critical Smithkline Beecham Plc
Publication of AR020614A1 publication Critical patent/AR020614A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método para reducir o prevenir la apoptosis de células diferenciadas seleccionadas entre la lista que consta de miocitos cardíacos, células betapancreáticas, células endoteliales y células neuronales en un mamífero o no humano, cuyo método comprende la administracion, inclusive la administracion enrégimen agudo, de una cantidad no toxica y eficaz de un intensificador de la absorcion de glucosa a un mamífero humano o no humano que necesita de ello.
ARP990103577A 1998-07-21 1999-07-21 Nuevo metodo AR020614A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound

Publications (1)

Publication Number Publication Date
AR020614A1 true AR020614A1 (es) 2002-05-22

Family

ID=26314086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103577A AR020614A1 (es) 1998-07-21 1999-07-21 Nuevo metodo

Country Status (35)

Country Link
EP (2) EP1523980A3 (es)
JP (1) JP2002521325A (es)
KR (1) KR20010079550A (es)
CN (1) CN1167416C (es)
AP (1) AP1416A (es)
AR (1) AR020614A1 (es)
AT (1) ATE318588T1 (es)
AU (1) AU5053599A (es)
BG (1) BG105251A (es)
BR (1) BR9912144A (es)
CA (1) CA2338216A1 (es)
CO (1) CO5060465A1 (es)
CY (1) CY1106078T1 (es)
CZ (1) CZ2001250A3 (es)
DE (1) DE69930125T2 (es)
DK (1) DK1098638T3 (es)
DZ (1) DZ2854A1 (es)
EA (1) EA004772B1 (es)
ES (1) ES2259839T3 (es)
GC (1) GC0000173A (es)
HU (1) HUP0103870A3 (es)
ID (1) ID27850A (es)
IL (1) IL140741A0 (es)
MA (1) MA26662A1 (es)
NO (1) NO20010293L (es)
NZ (1) NZ509175A (es)
OA (1) OA11583A (es)
PE (1) PE20000881A1 (es)
PL (1) PL345663A1 (es)
PT (1) PT1098638E (es)
SI (1) SI1098638T1 (es)
SK (1) SK1022001A3 (es)
TR (1) TR200100208T2 (es)
TW (2) TWI239836B (es)
WO (1) WO2000004889A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
BR0017254A (pt) * 2000-06-16 2004-01-06 Smithkline Beecham Plc Tratamento e prevenção de condições associadas à resistência cardìaca à insulina
CA2452159A1 (en) 2001-07-23 2003-02-06 Galileo Laboratories, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
IL128771A0 (en) * 1996-09-12 2000-01-31 Sankyo Co An agent for enhancing the activity of glutathione reductase containing troglitazone and use thereof
EP1047423B1 (en) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Novel apoptosis inhibitors
AU2781899A (en) * 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
CO5060465A1 (es) 2001-07-30
EP1098638B1 (en) 2006-03-01
AP2001002033A0 (en) 2001-03-31
AP1416A (en) 2005-06-13
EP1523980A3 (en) 2009-03-18
KR20010079550A (ko) 2001-08-22
DK1098638T3 (da) 2006-06-19
TWI239836B (en) 2005-09-21
IL140741A0 (en) 2002-02-10
DE69930125T2 (de) 2006-10-05
CY1106078T1 (el) 2011-06-08
NO20010293D0 (no) 2001-01-18
SK1022001A3 (en) 2001-08-06
EP1098638A1 (en) 2001-05-16
TW200307532A (en) 2003-12-16
EP1523980A2 (en) 2005-04-20
CA2338216A1 (en) 2000-02-03
PL345663A1 (en) 2002-01-02
EA004772B1 (ru) 2004-08-26
BR9912144A (pt) 2001-04-03
AU5053599A (en) 2000-02-14
CN1167416C (zh) 2004-09-22
SI1098638T1 (sl) 2006-06-30
JP2002521325A (ja) 2002-07-16
BG105251A (en) 2001-10-31
WO2000004889A1 (en) 2000-02-03
ID27850A (id) 2001-04-26
OA11583A (en) 2004-07-01
TR200100208T2 (tr) 2001-05-21
CN1310619A (zh) 2001-08-29
NZ509175A (en) 2003-10-31
NO20010293L (no) 2001-03-07
HUP0103870A2 (hu) 2002-05-29
DE69930125D1 (de) 2006-04-27
ATE318588T1 (de) 2006-03-15
HUP0103870A3 (en) 2003-06-30
DZ2854A1 (fr) 2003-12-01
GC0000173A (en) 2006-03-29
CZ2001250A3 (cs) 2002-03-13
PT1098638E (pt) 2006-07-31
MA26662A1 (fr) 2004-12-20
ES2259839T3 (es) 2006-10-16
EA200100164A1 (ru) 2001-08-27
PE20000881A1 (es) 2000-10-07

Similar Documents

Publication Publication Date Title
AR054732A1 (es) Articulo absorbente tipo bombacha
SV2002000315A (es) Combinaciones de productos activos con propiedades insecticidas y acaricidas ref. lea 34226-sv
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
AR017736A1 (es) Articulo absorbente con mejores propiedades de contencion de heces
BR0100026B1 (pt) artigo absorvente decomponÍvel em Água.
CY1110721T1 (el) Χρηση glp-2 σε συνδυασμο με αλλο θεραπευτικο παραγοντα σε οστικες παθησεις
ZA992005B (en) Proton donating actives in absorbent articles.
AR051704A1 (es) Composicion para el consumo humano que brinda mejoras en la concentracion de la agudeza mental
ES2137372T3 (es) Solucion antifungica para las uñas.
CY1107649T1 (el) Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος
AR075909A1 (es) Un articulo absorbente.
BR9710560B1 (pt) Composição farmacêutica contendo clopidogrel e sinvastatina, bem como seus usos.
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
ECSP034638A (es) Un articulo absorbente tal como una toalla sanitaria, un pañal, un protector para incontinencia o un protector diario
BR0100025B1 (pt) artigo absorvente decomponìvel em água.
PE102199A1 (es) Articulos absorbentes desechables que tienen un mejor ajuste a la anatomia del cuerpo
RS50769B (sr) Antitumorska kombinacija koja sadrži vegf-zamku i 5fu ili jedan od njegovih derivata
AR020455A1 (es) Composicion insecticida
AR020614A1 (es) Nuevo metodo
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
SE9803272D0 (sv) A drug for cell regeneration
AR015956A1 (es) Composiciones de citoquinas oromucosales y usos de las mismas
BR0002751B1 (pt) composiÇÕes e mÉtodos para atrair os gorgulhos do algodço que migram no inverno.
ECSP993063A (es) Nuevo metodo para reducir o prevenir la apoptosis de celulas diferenciadas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal